Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Needham & Company LLC 

Rhythm Pharmaceuticals diskutieren

Rhythm Pharmaceuticals

WKN: A2H5A0 / Symbol: RYTM / Name: Rhythm Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

37,20 €
0,00 %

Einschätzung Buy
Rendite (%) 69,83 %
Kursziel 30,22
Veränderung
Endet am 02.03.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 69,83 %
Kursziel 33,06
Veränderung
Endet am 02.03.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $35.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 69,83 %
Kursziel 42,45
Veränderung
Endet am 02.03.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $40.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 85,85 %
Kursziel 52,93
Veränderung
Endet am 02.03.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $52.00 to $56.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 69,09 %
Kursziel 29,25
Veränderung
Endet am 02.08.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 43,08 %
Kursziel 37,40
Veränderung
Endet am 08.11.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $38.00 to $40.00. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,08 %
Kursziel 41,69
Veränderung
Endet am 07.12.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $32.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,08 %
Kursziel 38,96
Veränderung
Endet am 07.12.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $38.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) -12,26 %
Kursziel 50,16
Veränderung
Endet am 19.12.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $55.00 price target on the stock, up previously from $29.00.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) -12,26 %
Kursziel 48,34
Veränderung
Endet am 19.12.24

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $48.00 to $53.00. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,00 %
Kursziel 45,63
Veränderung
Endet am 04.01.25

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $45.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,82 %
Kursziel 47,88
Veränderung
Endet am 25.01.25

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $42.00 to $52.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,27 %
Kursziel 45,98
Veränderung
Endet am 26.01.25

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,14 %
Kursziel 46,19
Veränderung
Endet am 22.02.25

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,13 %
Kursziel 46,37
Veränderung
Endet am 10.04.25

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 3,35 %
Kursziel 46,64
Veränderung
Endet am 26.04.25

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,64 %
Kursziel 42,78
Veränderung
Endet am 07.05.25

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Needham & Company LLC from $50.00 to $46.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat